<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20241212011657&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20241212011657&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 12 Dec 2024 06:16:58 +0000</lastbuilddate>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Left atrial appendage closure after ablation: the best OPTION for patients with AF?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39663367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Dec 11. doi: 10.1038/s41569-024-01113-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39663367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39663367</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01113-y>10.1038/s41569-024-01113-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39663367</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Left atrial appendage closure after ablation: the best OPTION for patients with AF?</dc:title>
<dc:identifier>pmid:39663367</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01113-y</dc:identifier>
</item>
<item>
<title>Reply: Considerations on the SI! Program for Elementary Schools Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39663012/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 17;84(25):e357-e358. doi: 10.1016/j.jacc.2024.09.1241.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39663012/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39663012</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1241>10.1016/j.jacc.2024.09.1241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39663012</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Gloria Santos-Beneit</dc:creator>
<dc:creator>Rodrigo Fernández-Jiménez</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>SI! Program for Elementary Schools Trial Investigators</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Considerations on the SI! Program for Elementary Schools Trial</dc:title>
<dc:identifier>pmid:39663012</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1241</dc:identifier>
</item>
<item>
<title>Effect of Time-Varying Exposure to School-Based Health Promotion on Adiposity in Childhood</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39663011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 17;84(25):e355. doi: 10.1016/j.jacc.2024.08.084.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39663011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39663011</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.084>10.1016/j.jacc.2024.08.084</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39663011</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Ying Fang</dc:creator>
<dc:creator>Changlin Zhai</dc:creator>
<dc:creator>Haihua Pan</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Time-Varying Exposure to School-Based Health Promotion on Adiposity in Childhood</dc:title>
<dc:identifier>pmid:39663011</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.084</dc:identifier>
</item>
<item>
<title>Refining Health Interventions: Addressing Developmental Differences and Focusing on Creative Thinking in Children</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39663010/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 17;84(25):e353-e354. doi: 10.1016/j.jacc.2024.08.086.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39663010/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39663010</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.086>10.1016/j.jacc.2024.08.086</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39663010</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Hanjun Ma</dc:creator>
<dc:creator>Jiangmi Mo</dc:creator>
<dc:creator>Zonglong He</dc:creator>
<dc:creator>Qunqiang Luo</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Refining Health Interventions: Addressing Developmental Differences and Focusing on Creative Thinking in Children</dc:title>
<dc:identifier>pmid:39663010</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.086</dc:identifier>
</item>
<item>
<title>REPLY: Generalizability of the Mass General Brigham Lp(a) Registry Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39663009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 17;84(25):e351-e352. doi: 10.1016/j.jacc.2024.09.1239.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39663009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39663009</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1239>10.1016/j.jacc.2024.09.1239</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39663009</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam N Berman</dc:creator>
<dc:creator>David W Biery</dc:creator>
<dc:creator>Brittany N Weber</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>None Ron Blankstein</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>REPLY: Generalizability of the Mass General Brigham Lp(a) Registry Study</dc:title>
<dc:identifier>pmid:39663009</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1239</dc:identifier>
</item>
<item>
<title>Generalizability of the Mass General Brigham Lp(a) Registry Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39663008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 17;84(25):e349. doi: 10.1016/j.jacc.2024.08.085.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39663008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39663008</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.085>10.1016/j.jacc.2024.08.085</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39663008</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Kazuo Komamura</dc:creator>
<dc:creator>Hiroshi Miyake</dc:creator>
<dc:creator>Koichi Kobayashi</dc:creator>
<dc:creator>Mitsunori Iwase</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Generalizability of the Mass General Brigham Lp(a) Registry Study</dc:title>
<dc:identifier>pmid:39663008</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.085</dc:identifier>
</item>
<item>
<title>Acute Respiratory Infections Fuel Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39663007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 17;84(25):2468-2470. doi: 10.1016/j.jacc.2024.10.079.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39663007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39663007</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.079>10.1016/j.jacc.2024.10.079</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39663007</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Florien S van Royen</dc:creator>
<dc:creator>Roderick P Venekamp</dc:creator>
<dc:creator>Patricia C J L Bruijning-Verhagen</dc:creator>
<dc:creator>Frans H Rutten</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Acute Respiratory Infections Fuel Cardiovascular Disease</dc:title>
<dc:identifier>pmid:39663007</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.079</dc:identifier>
</item>
<item>
<title>Improving Outcome in Patients With Tricuspid Regurgitation: Look At the Kidneys and the Liver!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39663006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 17;84(25):2457-2459. doi: 10.1016/j.jacc.2024.09.1238.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39663006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39663006</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1238>10.1016/j.jacc.2024.09.1238</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39663006</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Marianna Adamo</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Improving Outcome in Patients With Tricuspid Regurgitation: Look At the Kidneys and the Liver!</dc:title>
<dc:identifier>pmid:39663006</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1238</dc:identifier>
</item>
<item>
<title>Mediterranean diet, neutrophil count, and carotid intima-media thickness in secondary prevention: the CORDIOPREV study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings suggest that neutrophils may represent a promising target for preventing atherosclerosis. A Mediterranean diet could serve as an effective dietary strategy to reduce neutrophil levels and potentially slow the progression of atherosclerosis, offering a new neutrophil-reducing therapy concept. Further research is essential to gain deeper insights into the role of neutrophils in the pathophysiology of atherosclerotic cardiovascular disease in humans.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae836. doi: 10.1093/eurheartj/ehae836. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Several studies have supported the role of innate immune system as a key factor in the sterile inflammation underlying the pathophysiology of atherosclerosis in mice. However, its involvement in humans remains unclear. This study aimed to explore the association between neutrophil count, and the intima-media thickness of common carotid arteries (IMT-CC), as well as the potential impact of long-term dietary interventions on these associations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive analysis was conducted within the framework of the CORDIOPREV study, a long-term secondary prevention study involving dietary interventions with either a Mediterranean or a low-fat diet. The study evaluated the relationship between absolute neutrophil count and neutrophil-related ratios with IMT-CC at baseline and after 5 and 7 years of dietary intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, patients in the highest tertile of neutrophil count had a higher IMT-CC and number of carotid plaques, when compared to lowest tertile (P &lt; .01 and P &lt; .05, respectively). Logistic regression analyses supported this association. Elevated neutrophil count, neutrophil-to-erythrocyte ratio, and neutrophil-to-HDL ratio were associated with an increased likelihood of having an IMT-CC >;.9 mm {odds ratio (OR) 1.17 [95% confidence interval (CI) 1.04-1.35], OR 2.21 (95% CI 1.24-4.12), and OR 1.96 (95% CI 1.09-3.55), respectively}, after adjustment for all variables, which was corroborated by linear regression. Furthermore, a linear mixed-effect model analysis from a longitudinal analysis spanning 5 and 7 years revealed an increase in 1 unit of neutrophils/μl at these time points was associated with a mean increase of .004 (.002) mm in the IMT-CC (P = .031) after adjustment for all variables. Interestingly, in patients exhibiting regression in IMT-CC after 7 years of follow-up, those following a Mediterranean diet showed a significant decrease in neutrophil count after 5 and 7 years (both with P &lt; .05), compared to baseline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings suggest that neutrophils may represent a promising target for preventing atherosclerosis. A Mediterranean diet could serve as an effective dietary strategy to reduce neutrophil levels and potentially slow the progression of atherosclerosis, offering a new neutrophil-reducing therapy concept. Further research is essential to gain deeper insights into the role of neutrophils in the pathophysiology of atherosclerotic cardiovascular disease in humans.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661486</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae836>10.1093/eurheartj/ehae836</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661486</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Hatim Boughanem</dc:creator>
<dc:creator>José D Torres-Peña</dc:creator>
<dc:creator>Antonio Pablo Arenas-de Larriva</dc:creator>
<dc:creator>Juan L Romero-Cabrera</dc:creator>
<dc:creator>Purificación Gómez-Luna</dc:creator>
<dc:creator>Laura Martín-Piedra</dc:creator>
<dc:creator>Fernando Rodríguez-Cantalejo</dc:creator>
<dc:creator>Francisco J Tinahones</dc:creator>
<dc:creator>Elena M Yubero Serrano</dc:creator>
<dc:creator>Oliver Soehnlein</dc:creator>
<dc:creator>Pablo Perez-Martinez</dc:creator>
<dc:creator>Javier Delgado-Lista</dc:creator>
<dc:creator>José López-Miranda</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mediterranean diet, neutrophil count, and carotid intima-media thickness in secondary prevention: the CORDIOPREV study</dc:title>
<dc:identifier>pmid:39661486</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae836</dc:identifier>
</item>
<item>
<title>Successful diagnosis and surgical treatment of tuberculous pericarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661483/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae841. doi: 10.1093/eurheartj/ehae841. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661483/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661483</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae841>10.1093/eurheartj/ehae841</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661483</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Li Yang</dc:creator>
<dc:creator>Liqun He</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Successful diagnosis and surgical treatment of tuberculous pericarditis</dc:title>
<dc:identifier>pmid:39661483</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae841</dc:identifier>
</item>
<item>
<title>Prognostic impact of inducible ischaemia in ischaemic left ventricular dysfunction: the REVIVED-BCIS2 trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661477/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae844. doi: 10.1093/eurheartj/ehae844. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661477/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661477</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae844>10.1093/eurheartj/ehae844</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661477</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Holly Morgan</dc:creator>
<dc:creator>Muhummad Sohaib Nazir</dc:creator>
<dc:creator>Matthew E Li Kam Wa</dc:creator>
<dc:creator>Gerry P McCann</dc:creator>
<dc:creator>John P Greenwood</dc:creator>
<dc:creator>Adam K McDiarmid</dc:creator>
<dc:creator>Matthew Dodd</dc:creator>
<dc:creator>Matthew Ryan</dc:creator>
<dc:creator>Divaka Perera</dc:creator>
<dc:creator>Amedeo Chiribiri</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prognostic impact of inducible ischaemia in ischaemic left ventricular dysfunction: the REVIVED-BCIS2 trial</dc:title>
<dc:identifier>pmid:39661477</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae844</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Pushing the boundaries of transcatheter aortic valve implantation in asymptomatic patients with severe aortic stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae839. doi: 10.1093/eurheartj/ehae839. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661473</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae839>10.1093/eurheartj/ehae839</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661473</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Pushing the boundaries of transcatheter aortic valve implantation in asymptomatic patients with severe aortic stenosis</dc:title>
<dc:identifier>pmid:39661473</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae839</dc:identifier>
</item>
<item>
<title>The '10 commandments' of the 2024 European Society of Cardiology guidelines for the management of chronic coronary syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661412/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae778. doi: 10.1093/eurheartj/ehae778. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661412</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae778>10.1093/eurheartj/ehae778</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661412</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Christiaan J M Vrints</dc:creator>
<dc:creator>Felicita Andreotti</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The '10 commandments' of the 2024 European Society of Cardiology guidelines for the management of chronic coronary syndromes</dc:title>
<dc:identifier>pmid:39661412</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae778</dc:identifier>
</item>
<item>
<title>Artificial intelligence in patients with atrial fibrillation to manage clinical complexity and comorbidities: the ARISTOTELES project</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae792. doi: 10.1093/eurheartj/ehae792. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661409</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae792>10.1093/eurheartj/ehae792</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661409</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>Davide Antonio Mei</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>ARISTOTELES Consortium</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence in patients with atrial fibrillation to manage clinical complexity and comorbidities: the ARISTOTELES project</dc:title>
<dc:identifier>pmid:39661409</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae792</dc:identifier>
</item>
<item>
<title>European Research Council-funded grant: unveiling the effect of chemicals on lipids</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661406/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae758. doi: 10.1093/eurheartj/ehae758. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661406/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661406</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae758>10.1093/eurheartj/ehae758</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661406</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Tina Kold Jensen</dc:creator>
<dc:creator>Iben Have Beck</dc:creator>
<dc:creator>Christian Lars Lund</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Research Council-funded grant: unveiling the effect of chemicals on lipids</dc:title>
<dc:identifier>pmid:39661406</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae758</dc:identifier>
</item>
<item>
<title>Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661383/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased. Overall prescription of ARNI at discharge was 55.4% in eligible patients at the end of the study, suggesting remaining opportunity for continued improvement in ARNI prescription.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 11. doi: 10.1001/jamacardio.2024.3815. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failure with reduced ejection fraction (HFrEF), ie, those with an EF of 40% or less.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To describe national longitudinal trends in ARNI prescribing patterns among hospitalized patients with HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, hospitalized patients with HFrEF at 614 participating hospitals were identified. Rates of ARNI, angiotensin converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) prescription at discharge were evaluated across 3 time periods. Adjusted logistic regression and piecewise logistic regression were used to evaluate the impact of publication dates on ARNI prescription rates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: ARNI prescribing patterns in hospitalized patients with HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Rates of ARNI, ACEI, and ARB prescription at discharge were evaluated across 3 time periods as follows: (1) period 1 included the US Food and Drug Administration (FDA) approval of sacubitril-valsartan to the day before the PIONEER-HF (Comparison of Sacubitril-Valsartan vs Enalapril on Effect on N-Terminal Pro-Brain Natriuretic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication (July 7, 2015-November 10, 2018); (2) period 2 included the day of the PIONEER-HF trial publication to the day before publication of the 2021 Update to the 2017 Consensus for Optimization of Heart Failure Treatment (November 11, 2018-January 10, 2021); and (3) period 3 included the day of the 2021 update publication to the last available data at the time of analysis (January 11, 2021-December 31, 2022).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 114 333 hospitalized patients (mean [IQR] age, 67.0 [57.0-78.0] years; 74 765 male [65.4%]) were included in this study. Rates of ARNI prescribed at discharge increased from 1.1% (27 of 2451) during July 7, 2015, to September 30, 2015, to 55.4% (1957 of 3536) during October 1, 2022, to December 31, 2022. ACEI or ARB prescription at discharge fell from 88.3% (2612 of 2957) to 45.9% (2033 of 4434) over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to 84.7% (3990 of 4711). In adjusted logistic regression models, compared with period 1, patients discharged during period 2 and period 3 were found to have a 3.81-fold (95% CI, 3.65-3.98) and 9.15-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45-0.48) and 0.25 (95% CI, 0.24-0.26) decreased odds of ACEI or ARB prescription at discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased. Overall prescription of ARNI at discharge was 55.4% in eligible patients at the end of the study, suggesting remaining opportunity for continued improvement in ARNI prescription.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661383/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661383</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3815>10.1001/jamacardio.2024.3815</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661383</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Pratyaksh K Srivastava</dc:creator>
<dc:creator>Alexandra M Klomhaus</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Paul Heidenreich</dc:creator>
<dc:creator>Sabra C Lewsey</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure</dc:title>
<dc:identifier>pmid:39661383</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3815</dc:identifier>
</item>
<item>
<title>Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this secondary analysis of the REPRIEVE randomized clinical trial suggest that PCOLCE may be associated with the atherosclerotic plaque stabilization effects of statins by promoting collagen deposition in the extracellular matrix transforming vulnerable plaque phenotypes to more stable coronary lesions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 11. doi: 10.1001/jamacardio.2024.4115. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene pathways contributing to changes in coronary plaque remain unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To use targeted discovery proteomics and transcriptomics approaches to interrogate biological pathways beyond low-density lipoprotein cholesterol (LDL-C), relating statin outcomes to reduce NCP volume and promote plaque stabilization among people with HIV (PWH).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the double-blind, placebo-controlled, REPRIEVE randomized clinical trial. Participants underwent coronary computed tomography angiography (CTA), plasma protein analysis, and transcriptomic analysis at baseline and 2-year follow-up. The trial enrolled PWH from April 2015 to February 2018 at 31 US research sites. PWH without known cardiovascular diseases taking antiretroviral therapy and with low to moderate 10-year cardiovascular risk were eligible. Data analyses were conducted from October 2023 to February 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Oral pitavastatin calcium, 4 mg per day.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Relative change in plasma proteomics, transcriptomics, and noncalcified plaque volume among those receiving treatment vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 558 individuals (mean [SD] age, 51 [6] years; 455 male [82%]) included in the proteomics assessment, 272 (48.7%) received pitavastatin and 286 (51.3%) received placebo. After adjusting for false discovery rates, pitavastatin increased abundance of procollagen C-endopeptidase enhancer 1 (PCOLCE), neuropilin 1 (NRP-1), major histocompatibility complex class I polypeptide-related sequence A (MIC-A) and B (MIC-B), and decreased abundance of tissue factor pathway inhibitor (TFPI), tumor necrosis factor ligand superfamily member 10 (TRAIL), angiopoietin-related protein 3 (ANGPTL3), and mannose-binding protein C (MBL2). Among these proteins, the association of pitavastatin with PCOLCE (a rate-limiting enzyme of collagen deposition) was greatest, with an effect size of 24.3% (95% CI, 18.0%-30.8%; P &lt; .001). In a transcriptomic analysis, individual collagen genes and collagen gene sets showed increased expression. Among the 195 individuals with plaque at baseline (88 [45.1%] taking pitavastatin, 107 [54.9%] taking placebo), changes in NCP volume were most strongly associated with changes in PCOLCE (%change NCP volume/log2-fold change = -31.9%; 95% CI, -42.9% to -18.7%; P &lt; .001), independent of changes in LDL-C level. Increases in PCOLCE related most strongly to change in the fibro-fatty (&lt;130 Hounsfield units) component of NCP (%change fibro-fatty volume/log2-fold change = -38.5%; 95% CI, -58.1% to -9.7%; P = .01) with a directionally opposite, although nonsignificant, increase in calcified plaque (%change calcified volume/log2-fold change = 34.4%; 95% CI, -7.9% to 96.2%; P = .12).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this secondary analysis of the REPRIEVE randomized clinical trial suggest that PCOLCE may be associated with the atherosclerotic plaque stabilization effects of statins by promoting collagen deposition in the extracellular matrix transforming vulnerable plaque phenotypes to more stable coronary lesions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02344290.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661372</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4115>10.1001/jamacardio.2024.4115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661372</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Márton Kolossváry</dc:creator>
<dc:creator>Samuel R Schnittman</dc:creator>
<dc:creator>Markella V Zanni</dc:creator>
<dc:creator>Kathleen V Fitch</dc:creator>
<dc:creator>Carl J Fichtenbaum</dc:creator>
<dc:creator>Judith A Aberg</dc:creator>
<dc:creator>Gerald S Bloomfield</dc:creator>
<dc:creator>Carlos D Malvestutto</dc:creator>
<dc:creator>Judith Currier</dc:creator>
<dc:creator>Marissa R Diggs</dc:creator>
<dc:creator>Christopher deFilippi</dc:creator>
<dc:creator>Allison Ross Eckard</dc:creator>
<dc:creator>Adrian Curran</dc:creator>
<dc:creator>Murat Centinbas</dc:creator>
<dc:creator>Ruslan Sadreyev</dc:creator>
<dc:creator>Borek Foldyna</dc:creator>
<dc:creator>Thomas Mayrhofer</dc:creator>
<dc:creator>Julia Karady</dc:creator>
<dc:creator>Jana Taron</dc:creator>
<dc:creator>Sara McCallum</dc:creator>
<dc:creator>Michael T Lu</dc:creator>
<dc:creator>Heather J Ribaudo</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:creator>Steven K Grinspoon</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39661372</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4115</dc:identifier>
</item>
<item>
<title>In Vitro, but Not Yet In Vivo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 11. doi: 10.1001/jamacardio.2024.4363. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661353/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661353</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4363>10.1001/jamacardio.2024.4363</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661353</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Victoria R Bradford</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>In Vitro, but Not Yet In Vivo</dc:title>
<dc:identifier>pmid:39661353</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4363</dc:identifier>
</item>
<item>
<title>Error in Figure 1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661084/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 1;9(12):1174. doi: 10.1001/jamacardio.2024.4487.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661084/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661084</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4487>10.1001/jamacardio.2024.4487</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661084</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure 1</dc:title>
<dc:identifier>pmid:39661084</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4487</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39661083/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 1;9(12):1068. doi: 10.1001/jamacardio.2023.3687.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39661083/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39661083</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3687>10.1001/jamacardio.2023.3687</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39661083</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:39661083</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3687</dc:identifier>
</item>
<item>
<title>Illuminating data: how the new ESC Atlas can help chart a healthier future across Europe</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39660413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241212011657&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 11:ehae865. doi: 10.1093/eurheartj/ehae865. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39660413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241212011657&v=2.18.0.post9+e462414">39660413</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae865>10.1093/eurheartj/ehae865</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39660413</guid>
<pubDate>Wed, 11 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-12-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Illuminating data: how the new ESC Atlas can help chart a healthier future across Europe</dc:title>
<dc:identifier>pmid:39660413</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae865</dc:identifier>
</item>





























</channel>
</rss>